Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed high-grade glioma (WHO grade III or IV)~* Must be scheduled to receive standard first-line therapy (cranial radiotherapy and temozolomide)~PATIENT CHARACTERISTICS:~* ANC ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Creatinine ≤ 1.7 mg/dL~* Bilirubin ≤ 1.5 mg/dL~* Transaminases ≤ 4 times upper limit of normal~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other malignancy within the past 5 years except curatively treated carcinoma in situ or basal cell carcinoma of the skin~PRIOR CONCURRENT THERAPY:~* No prior hormonal therapy for brain tumor~* No prior biological agents (including immunotoxins, immunoconjugates, antisense agents, peptide receptor antagonists, interferons, interleukins, tumor-infiltrating lymphocytes, lymphokine-activated killer cells, or gene therapy)~* No prior immunotherapy~* No prior chemotherapy~* No prior radiotherapy, including cranial radiotherapy~* Concurrent glucocorticoid therapy allowed~* No concurrent carbamazepine~* No other concurrent experimental therapy~* No other concurrent cytotoxic therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).